Description: Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
Home Page: poseida.com
9390 Towne Centre Drive
San Diego,
CA
92121
United States
Phone:
858 779 3100
Officers
| Name | Title |
|---|---|
| Mr. Mark J. Gergen J.D. | Executive Chairman of the Board |
| Dr. Kristin Yarema Ph.D. | President, CEO & Director |
| Ms. Johanna M. Mylet CPA | Chief Financial Officer |
| Mr. Loren Wagner | Chief Operations Officer |
| Ms. Kristin Martin | Chief People & Administration Officer |
| Mr. Alexander Chapman | Senior VP of Investor Relations & Corporate Communications |
| Mr. Harry J. Leonhardt Esq., J.D. | General Counsel, Chief Compliance Officer & Corporate Secretary |
| Dr. Devon J. Shedlock Ph.D. | Chief Scientific Officer of Cell Therapy |
| Ms. Lisa Portale | Senior Vice President of Regulatory Affairs |
| Dr. Jeffrey W. Winkelman J.D., Ph.D. | Senior VP & Chief Patent Counsel |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 10.2981 |
| Price-to-Sales TTM: | 5.7343 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 350 |